Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

CompletedOBSERVATIONAL

Enrollment

13,680

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions

SARS-CoV-2

Trial Locations (1)

CMIC Co., Ltd, Tokyo

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY